Improvement of the drug therapy results in patients with high blood pressure at a community pharmacy
Keywords:
Community Pharmacy, Drug Related Problems, Drug Therapy Monitoring, Hypertension, Negative Results Associated to the Medication, Pharmaceutical Care, Therapeutic ComplianceAbstract
In the present work, the consequences of the sanitary assistance activity of the pharmacist in a group of patientswith high blood pressure are analyzed. The Drug Related Problems (DRP), detected in these patients at a communitypharmacy, that could generate Negative Results Associated to the Medication (NRM) were studied, carrying out aclassifi cation with respect to the pharmacotherapy qualities of necessity, effectiveness and security. The impact ofthe communication channel used in the intervention (pharmacist-patient or pharmacist-patient-doctor) in its fi nalresult was also studied. Better result was obtained when the collaboration with the doctor was selected. This studyalso remarks the need to overcome some barriers that hinders a better application of this pharmacotherapeuticmonitoring service and a greater integration of patients.Downloads
References
Centro Andaluz de Información de Medicamentos (CADIME). Tratamiento de la HTA: aspectos controvertidos. Boletín Terapéutico Andaluz Monografía 2006; nº 22.
Nacional Institute for Clinical Excellence. Hypertension. Management of hypertension in adults in primary care. Clinical
Guideline 18. August 2004. Disponible en URL: www.nice.org.uk.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hipertension: analysis of world wide data. Lancet 2005; 365(9455): 217-223.
World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypetension. J Hypertens 2003; 21(11): 1983-1992.
Marín R, de la Sierra A, Armario P, Banegas JR, Campo C, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España. Med Clin (Barc) 2005: 125(1): 24-34.
Tisaire Sánchez J. Cumplimiento terapéutico en hipertensión arterial. Hypertens Rev 2004; 1(1): 2-6.
Coca Payeras A. Evolución del control de la hipertensión arterial en atención primaria en España. Resultados del estudio Controlares 2003. Hipertensión 2005; 22(1): 5-14.
Freeth D, Reeves S. Learning to work together: using the presage, process, product (3P) model to highlight decisions and possibilities. J Interprof Care 2004; 18(1): 43-56.
Ferro LA, Marcrom RE, Garrelts L, Bennett SM, Boyd EE, Eddinger L, Shafer RD, Fields ML. Collaborative practice agreements between pharmacists and physicians. J Am Pharm Assoc 1998; 38: 655-664.
Wake-Dyster W. Designing teams that work. Australian Health Review 2001; 24(4): 34-41.
Amariles P, Machuca M, Jiménez-Faus A, Silva-Castro MM, Sabater D, Baena MI, Jiménez-Martín J, Faus MJ. Riesgo cardiovascular: componentes, valoración e intervenciones preventivas. Ars Pharmaceutica 2004; 45: 187-210.
Amariles P, Baena MI, Faus FJ, Machuca M, Tudela J, Barris D, Sevilla J, Román-Alvarado J, Machuca MP, Cansino J. Conocimiento y riesgo cardiovascular en pacientes en tratamiento con medicamentos cardiovasculares. Ars Pharmaceutica 2005; 46(3): 279-300.
Barris D, Faus MJ. Iniciación a la metodología Dáder de seguimiento farmacoterapéutico en una farmacia comunitaria. Ars Pharmaceutica 2003; 44(3): 225-237.
Álvarez de Toledo F, Arcos-González P, Eyaralar-Riera T, Abal-Ferrer F, Dago-Martínez A, Cabiedes-Miragaya L, Sánchez-Posada I, Álvarez-Sánchez G. Atención Farmacéutica en personas que han sufrido episodios coronarios agudos (estudio TOMCOR). Rev Esp Salud Pública 2001; 75: 375-388.
Armando PD, Semería N, Tenllado MI, Sola N. Programa Dáder en Argentina: Resultados del primer trimestre de actividades. Pharm Care Esp 2001; 3: 196-203.
García M, García E, Tena M, Urbon A. Seguimiento farmacoterapéutico en las farmacias, por los Colegios Oficiales
de Farmacéuticos de Aragón (I): Implantación de la metodología Dáder (Seguimiento Farmacoterapéutico). Pharm Care Esp 2002; 4: 231-241.
Martínez-Romero F, Fernández-Llimós F, Gastelurrutia MA, Parras M, Faus MJ. Programa Dáder de seguimiento del tratamiento farmacológico. Resultados de la fase piloto. Ars Pharmaceutica 2001; 42(1): 53-65.
Machuca M, Fernández-Llimós F, Faus MJ. Método Dáder. Guía de Seguimiento Farmacoterapéutico. Granada: GIAFUGR; 2003.
SEH-LELHA, SEC-HTA, SEMFYC, SED, SEGG, SEMERGEN, CGCOF ERICA, SEMEG, SEMI, SEN. Documento de Consenso Español 2006. Automedida de la presión arterial. 2006.
Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial. Grupos de Trabajo en Hipertensión. Automedida de la presión arterial. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial, 2003.
Foro de Atención Farmacéutica. Consulta las definiciones de PRM y RNM en Portalfarma. Farmacéuticos 2006; 316: 41.
Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Medicamentos 2007. Colección Consejo Plus. Madrid: CGCOF; 2007.
Ragburn WE. Sixth report of the Nacional Committee on prevention, detection, evaluation and treatment of high blood
pressure: a summary. J Reprod Med 1998; 43:444-450.
Metry JM, Meyer UA. Drug regimens compliance: issues in clinical trials and patients management. Chichester Jon Wiley; 1994.
Jones JK, Gorkun L, Lian JK. Discontinuation of medication and changes in treatment alter Stara of new courses of antihypertensive drug: a study of a United Kingdom population. BMJ 1995; 311: 293-295.
Machuca M, Martínez Romero F, Faus MJ. Informe farmacéutico-médico según la metodología Dáder para el seguimiento
farmacológico. Pharm Care Esp 2000; 2:358-363.
Herrera J. Objetivos de la atención farmacéutica. Aten Primaria 2002; 30(3): 183-187.
García de Viñuca B. Barreras que impiden el desarrollo de la atención farmacéutica. El farmacéutico 2002; 281:55-60.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
